Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Operating Leases data on file, last reported at $7.2 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $7.2 million, down 29.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.2 million (down 29.59% YoY), and the FY2025 annual result was $7.9 million, down 25.42% from the prior year.
• Operating Leases slipped to $7.2 million in Q1 2026 per ARTV's latest filing, from $7.9 million in the prior quarter.
• Over five years, Operating Leases peaked at $13.3 million in Q4 2023 and troughed at $7.2 million in Q1 2026.
• A 4-year average of $10.0 million and a median of $10.3 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2025 and 2026: Operating Leases slipped 19.27% in 2025, then dropped 29.59% in 2026.
• A 4-year view of Operating Leases shows it stood at $13.3 million in 2023, then fell by 20.62% to $10.6 million in 2024, then decreased by 25.42% to $7.9 million in 2025, then fell by 8.31% to $7.2 million in 2026.
• Business Quant data shows ARTV's Operating Leases at $7.2 million in Q1 2026, $7.9 million in Q4 2025, and $8.5 million in Q3 2025.